Matricelf

Matricelf is an Israeli biotechnology company in the field of regenerative medicine and tissue engineering.

The company develops a platform for autologous (personal) 3D production of tissues and organs for a variety of medical conditions.

Matricelf's technology enables the production of autologous engineered tissue composed of scaffold and cells derived from the patients. In this approach a small fatty tissue biopsy is taken from the patient. The cellular and extra cellular materials are separated. While the cells are reprogrammed to become pluripotent stem cells (iPSCs), the extra cellular materials are processed to become a personalized hydrogel. The cells are then encapsulated within the hydrogel and efficiently differentiated to form 3D neuronal networks of motor neurons. These neuronal implants are injected into the injured site and promote regeneration without rejections.

Matricelf’s technology aims to completely regenerate the future of medicine.

The company completed successful pre-clinical studies in a number of medical conditions such as acute Myocardial Infarction, Parkinson's Disease, Age related Macular Degeneration and more and in 2019, for the first time in human history , we printed the first ever three-dimensional human heart from human tissue.

Our first indication is Spinal Cord Injury.

Each year, there are tens of thousands of new cases of traumatic Spinal Cord Injuries that usually lead to paralysis.

Considering the fact that SCI patients have no suggested treatments and are expected to spend their life in a wheelchair motivated us to further develop the technology and specifically SCI implant.

In our pre-clinical animal studies, mice treated with our implants regained their walking ability both in acute and chronic spinal cord injury models.

Matricelf’s technology promises to completely revolutionize the treatment of these patients by offering the potential for one-time definitive treatment.